source
- CSL strikes up to $1.6B deal with Alentis for autoimmune drug with broad potentialCSL will co-develop and co-promote Alentis Therapeutics' anti-claudin-1 therapy lixudebart for kidney and liver conditions, including primary sclerosing cholangitis and a systemic autoimmune diseas…
- Swiss CDMOs and CROs experience rapid growth as global sponsors seek specialized manufacturing and decentralized trialsSwitzerland’s contract development and manufacturing organisations (CDMOs) and contract research organisations (CROs) are entering a new boom cycle, driven by rising global demand for specialised m…